Home Tags SGN-LIV1A

Tag: SGN-LIV1A

Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...

Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...

Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...

Breast cancer is a cancer which forms in breast tissue. Metastatic breast cancer occurs when the cancer has spread to other parts of the...

Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple...

Seattle Genetics has signed a clinical collaboration agreement with Genentech, a member of the Roche Group, for the evaluation of its investigational antibody-drug conjugate...

SGN-LIV1A Monotherapy Data Show 37% ORR in Heavily Pretreated Triple Negative...

Data from an ongoing phase I clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with particular focus on metastatic triple-negative breast...

SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with...

Data presented today from an ongoing phase I clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate or ADC being developed by Seattle Genetics for the...

Phase I Trial of SGN-LIV1A Initiated in LIV-1-Positive Metastatic Breast Cancer

A new phase I clinical trial was initiated late October 2013 to evaluate SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer. SGN-LIV1A is based...

Phase I Trial of Seattle Genetics’ SGN-LIV1A for Patients with LIV-1-Positive...

A new phase 1 clinical trial evaluating SGN-LIV1A for patients with LIV-1-positive metastatic breast cancer has started. SGN-LIV1A utilizes Seattle Genetics’ industry-leading antibody-drug conjugate...